LSTM Home > LSTM Research > LSTM Online Archive

Modified recombinant human IgG1‐Fc is superior to natural IVIG at inhibiting immune‐mediated demyelination

Baksmeier, Christine, Blundell, Pat ORCID: https://orcid.org/0000-0003-3386-5660, Steckel, Julia, Schultz, Verena, Gu, Quan, Da Silva Filipe, Ana, Kohl, Alain, Linnington, Chris, Lu, Dongli, Dell, Anne, Haslam, Stuart, Wang, Jiabin, Czajkowsky, Dan, Goebels, Norbert and Pleass, Richard ORCID: https://orcid.org/0000-0001-7438-8296 (2021) 'Modified recombinant human IgG1‐Fc is superior to natural IVIG at inhibiting immune‐mediated demyelination'. Immunology. (In Press)

[img] Text
Richard J Pleass2Immunology accepted paper.docx - Accepted Version
Restricted to Repository staff only until 20 April 2022.

Download (6MB)

Abstract

Intravenous immunoglobulin (IVIG) is an established treatment for numerous autoimmune conditions. Although Fc fragments derived from IVIG have shown efficacy in controlling immune thrombocytopenia (ITP) in children, the mechanisms of action are unclear and controversial. The aim of this study is to dissect IVIG effector mechanisms using further adapted Fc fragments on demyelination in an ex vivo model of the central nervous system (CNS)-immune interface. Using organotypic cerebellar slice cultures (OSC) from transgenic mice we induced extensive immune-mediated demyelination and oligodendrocyte loss with an antibody specific for myelin oligodendrocyte glycoprotein (MOG) and complement. Protective effects of adapted Fc fragments were assessed by live imaging of GFP expression, immunohistochemistry and confocal microscopy. Cysteine and glycan adapted Fc fragments protected OSC from demyelination in a dose-dependent manner where equimolar concentrations of either IVIG or control Fc were ineffective. The protective effects of the adapted Fc fragments are partly attributed to interference with complement-mediated oligodendroglia damage. Transcriptome analysis ruled out signatures associated with inflammatory or innate immune responses. Taken together our findings show that recombinant biomimetics can be made that are at least two hundred-fold more effective than IVIG in controlling demyelination by anti-MOG antibodies.

Item Type: Article
Subjects: QW Microbiology and Immunology > Antigens and Antibodies. Toxins and Antitoxins > QW 570 Serology.
QW Microbiology and Immunology > Antigens and Antibodies. Toxins and Antitoxins > QW 575 Antibodies
WL Nervous System > WL 140 Nervous system diseases (General)
Faculty: Department: Biological Sciences > Department of Tropical Disease Biology
Digital Object Identifer (DOI): https://doi.org/10.1111/imm.13341
Depositing User: Cathy Waldron
Date Deposited: 23 Apr 2021 14:49
Last Modified: 04 Jun 2021 10:23
URI: https://archive.lstmed.ac.uk/id/eprint/17656

Statistics

View details

Actions (login required)

Edit Item Edit Item